2021 Revenues ($USD) : $847,522,000
2021 R&D spend : $121,875,000
2021 Number of Employees : 1,725
Fiscal Year End : 3/31/2021
Key People : Michael Minogue, chair, president and CEO; Marc Began, VP and general counsel; Andrew Greenfield, VP and chief commercial officer; Karen Mahoney, head, global human resources; Laxmi Peri, VP, engineering; Matt Plano, VP, operations; Thorsten Siess, VP and CTO; Charles Simonton, VP and chief medical officer; Todd Trapp, VP and CFO; David Weber, SVP and COO.

About the company: Based in Danvers, Massachusetts, Abiomed develops medical technology that provides circulatory and oxygenation support. Founded in 1981 to develop an artificial heart, the company acquired Impella CardioSystems in 2005 and shifted focus from heart replacement to heart recovery with the Impella heart pump for improving blood flow and/or temporarily assisting with the pumping function of the heart. The company also develops the Breethe OXY-1 compact cardiopulmonary bypass system with extracorporeal membrane oxygenation (ECMO) technology designed to provide oxygenation while supporting patient mobility. Abiomed is led by President and CEO Michael Minogue, who has held the position since 2004. –SW